British pharmaceutical company GSK on Monday said it had agreed to buy a US company that specializes in the treatment of rare gastrointestinal cancer GIST. GSK said in a statement that it had ...

Drugmaker GSK has agreed to pay up to 1.15 billion US dollars (£950 million) for a US-based biopharmaceutical company which is developing rare cancer therapies. GSK said the acquisition of IDRx w ...

GSK acquires IDRx for $1 billion upfront, with $150M milestone payments; gains lead molecule IDRX-42 for gastrointestinal stromal tumors. IDRX-42 shows 53% ORR in 1 prior therapy line, targeting ...

British drug maker GSK on Monday said it will buy US biopharmaceutical company IDRx for up to $1.15 billion. The Boston-based biotechnology firm is developing therapeutics for the treatment of ...